Literature DB >> 8094730

Priming to heat shock proteins in infants vaccinated against pertussis.

G Del Giudice1, A Gervaix, P Costantino, C A Wyler, C Tougne, E R de Graeff-Meeder, J van Embden, R van der Zee, L Nencioni, R Rappuoli.   

Abstract

To investigate whether and in which proportion normal individuals experience a priming to microbial heat shock proteins (hsp), the presence of antibodies to two mycobacterial hsp was tested in serum sample from 2- to 4-mo-old children before and at different times after vaccination with the trivalent vaccine against tetanus, diphtheria, and pertussis (DTP). We show that 88.9% of infants vaccinated with DTP developed antibody responses to mycobacterial hsp. Such a response was due to the whole-cell pertussis component of the vaccine, because it was not observed in infants receiving an acellular pertussis vaccine. Antibodies and cells reactive to the mycobacterial 65-kDa hsp were also found in mice immunized with DTP. Interestingly, whole-cell pertussis vaccine-induced anti-hsp antibodies cross-reacted with the Escherichia coli GroEL hsp, and at a some extent with the human 60-kDa hsp, belonging to the same hsp family. These data suggest that priming of the immune system to hsp is a common phenomenon occurring very early in life.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094730

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  T-cell, antibody, and cytokine responses to homologs of the 60-kilodalton heat shock protein in Helicobacter pylori infection.

Authors:  S A Sharma; G G Miller; R A Peek; G Pérez-Pérez; M J Blaser
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Legionella pneumophila heat-shock protein-induced increase of interleukin-1 beta mRNA involves protein kinase C signalling in macrophages.

Authors:  C Retzlaff; Y Yamamoto; S Okubo; P S Hoffman; H Friedman; T W Klein
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

3.  Homogeneity of antibody responses in tuberculosis patients.

Authors:  K Samanich; J T Belisle; S Laal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway.

Authors:  K Suzue; X Zhou; H N Eisen; R A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.

Authors:  Ang Lin; Danijela Apostolovic; Maja Jahnmatz; Frank Liang; Sebastian Ols; Teghesti Tecleab; Chenyan Wu; Marianne van Hage; Ken Solovay; Keith Rubin; Camille Locht; Rigmor Thorstensson; Marcel Thalen; Karin Loré
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 6.  Immunity, autoimmunity and immunotherapy: new frontiers in heat shock protein research.

Authors:  C J Elson; S J Thompson
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

7.  Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV).

Authors:  Yong-Zhang Zhu; Cheng-Song Cai; Wei Zhang; Hong-Xiong Guo; Jin-Ping Zhang; Ya-Yong Ji; Guang-Yuan Ma; Jia-Lin Wu; Qing-Tian Li; Cheng-Ping Lu; Xiao-Kui Guo
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

Review 8.  Chaperonins in disease: mechanisms, models, and treatments.

Authors:  J C Ranford; B Henderson
Journal:  Mol Pathol       Date:  2002-08

Review 9.  Role of heat shock proteins in protection from and pathogenesis of infectious diseases.

Authors:  U Zügel; S H Kaufmann
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants.

Authors:  R Perraut; A R Lussow; S Gavoille; O Garraud; H Matile; C Tougne; J van Embden; R van der Zee; P H Lambert; J Gysin
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.